Evidence map›Paper›PMID 35326793›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Impact of the Acceptance of the Recommendations Made by a Meropenem Stewardship Program in a University Hospital: A Pilot Study.

Jorge Alba Fernandez, Jose Luis Del Pozo, Jose Leiva, Mirian Fernandez-Alonso, Irene Aquerreta, Azucena Aldaz, Andres Blanco, Jose Ramón Yuste

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jorge Alba FernandezInfectious Diseases Department, Hospital Universitario San Pedro, 26006 Logroño, Spain.
Jose Luis Del PozoInfectious Diseases Division, Clínica Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-5402-3334
Jose LeivaMicrobiology Division, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
Mirian Fernandez-AlonsoMicrobiology Division, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
Irene AquerretaPharmacy Division, Clínica Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-6074-5360
Azucena AldazPharmacy Division, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
Andres BlancoInfectious Diseases Division, Clínica Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0003-0674-2841
Jose Ramón YusteInfectious Diseases Division, Clínica Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-8502-9539

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial stewardship programs (ASP) promote appropriate antimicrobial use. We present a 4-year retrospective study that evaluated the clinical impact of the acceptance of the recommendations made by a meropenem-focused ASP. A total of 318 meropenem audits were performed. The ASP team (comprising infectious disease physicians, pharmacists and microbiologists) considered meropenem use in 96 audits (30.2%) to be inappropriate. The reasons to consider these uses inappropriate were the possibility of de-escalating to a narrower-spectrum antibiotic, in 66 (68.7%) audits, and unnecessary meropenem use, in 30 (31.3%) audits. The ASP team recommended de-escalation in 66 audits (68.7%) and discontinuation of meropenem in 30 audits (31.3%). ASP interventions were stratified according to whether or not recommendations were followed. The group in which recommendations were accepted and followed (i.e., accepted audit, AA) included 66 audits (68.7%) and the group in which recommendations were not followed (i.e., rejected audit, RA) included 30 (31.3%) audits. The comorbidity of the AA group (Charlson score) was higher than in the RA group (7.0 (5.0-9.0) vs. 6.0 (4.0-7.0),

Indexed as

antimicrobial stewardshipscarbapenemertapenem

Identifiers

PMID35326793
PMCPMC8944864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.